BoNT/E Receptor Identification via SV2A Glycosylation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The protein receptor for botulinum neurotoxin E (BoNT/E) has not been identified, and there is a need to determine if gangliosides serve as co-receptors for this toxin to design molecules that can inhibit its toxicity, as well as to target the enzymatic domain of BoNTs into non-neuronal cells for therapeutic applications.
Innovation Solution
The identification of glycosylated isoforms of the synaptic vesicle protein SV2, specifically SV2A and SV2B, as the protein receptors for BoNT/E, along with the role of gangliosides in mediating toxin entry, and the use of chimeric receptors and polypeptides to inhibit BoNT/E binding and entry.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If gangliosides are used as co-receptors for BoNT/E entry, then toxin binding affinity is improved, but specificity to neuronal cells is reduced
Solution Approach 1:
The patent combines two receptor components (SV2 protein and ganglioside) into a functional complex that mediates BoNT/E entry. This merging allows the toxin to achieve high binding affinity through the ganglioside component while maintaining neuronal specificity through the SV2 protein component, resolving the contradiction between affinity and specificity.
Solution Approach 2:
The SV2 protein acts as an intermediary that bridges the toxin and ganglioside. The toxin binds to the SV2-ganglioside complex, where SV2 provides the neuronal-specific recognition while ganglioside enhances binding affinity, thus mediating both functions simultaneously.
2Productivity
If BoNT/E enters neurons through SV2 receptors, then toxin entry efficiency is improved, but ability to target non-neuronal cells is lost
Solution Approach 1:
The patent segments the receptor system into its functional components (SV2 protein and ganglioside) and identifies the minimal essential elements for toxin entry. This segmentation allows for the development of engineered systems that can target different cell types by replacing or modifying the receptor components while maintaining the core entry mechanism.
Solution Approach 2:
The patent demonstrates that the SV2-ganglioside receptor complex serves multiple functions: it mediates natural neuronal uptake of BoNT/E and provides a targetable entry mechanism that can be applied to non-neuronal cells through engineered expression of SV2 or its domains, thus achieving universality.
3Reliability
If the complete SV2 protein is used as receptor, then BoNT/E binding is improved, but molecular complexity increases
Solution Approach 1:
The patent extracts the essential binding domain (L4 luminal domain) from the complete SV2 protein and demonstrates that this smaller domain retains the ability to mediate BoNT/E binding and entry. This extraction reduces molecular complexity while preserving the essential binding function.
Solution Approach 2:
The patent identifies that specific local regions of the SV2 protein (particularly the L4 luminal domain containing glycosylation sites) are responsible for toxin binding, rather than requiring the entire protein structure. This local quality approach allows functional reduction while maintaining binding reliability.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The study demonstrates that SV2A and SV2B mediate BoNT/E entry into neurons, with glycosylation and gangliosides being essential, providing a basis for developing inhibitors and targeting BoNTs to specific cells, including non-neuronal cells for therapeutic use.
Implementation Method 1
The heavy chain mediates cell-entry, via receptor-mediated endocytosis, and translocation of the light chain across the endosomal membrane into the cytosol
Implementation Method 2
SV2 contains twelve transmembrane domains with one large luminal domain (the fourth luminal domain, L4) between the seventh and eighth transmembrane domains. The BoNT/A binding site was mapped to a region within the SV2-L4 domain that contains two putative glycosylation sites
Implementation Method 3
Complex forms of gangliosides, called polysialiogangliosides (PSG), have been shown to bind BoNT/A, B and E with low affinity. It has not been reported whether gangliosides are essential for the entry of BoNT/E or BoNT/F into neurons
Implementation Method 4
The light chain is a protease that cleaves target proteins in cells. BoNT/E cleaves the peripheral membrane protein SNAP-25 (synaptosomal-associated protein of 25 kDa)
Data Source
AI summary
An isolated polypeptide comprising an amino acid sequence selected from amino acids 506-582 of SV2A, wherein position 573 is N and is glycosylated, or amino acids 449-525 of SV2B, wherein position 516 is N and is glycosylated. The present invention also provides an antibody that binds specifically to the polypeptide, an isolated nucleic acid comprising a polynucleotide that encodes the polypeptide; a method for reducing BoNT/E toxicity in an animal; a method for identifying an agent that blocks or inhibits binding between BoNT/E and an SV2A or SV2B protein; a method for monitoring synaptic vesicle endo- or exocytosis, a method for specifically delivering a chemical entity to a cell which has a specific receptor to a BoNT toxin. Also provided are a chimeric toxin for targeting a proteolytic domain of a toxin to a cell, the chimeric toxin comprising a catalytic or proteolytic domain of the BoNT toxin, and a ligand or a fragment thereof for a non-BoNT receptor on the cell; a method for targeting a proteolytic domain of a BoNT toxin to a cell, an isolated non-neuronal cell comprising a BoNT toxin receptor; and a method for screening for an inhibitor of a BoNT toxin.